Sponsor:
Washington University School of Medicine
Code:
NCT07914673
Conditions
Healthy Adult Participants
Age 65 and Older
Age 18 to 40
Immunology
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Trivalent inactivated influenza vaccine
RabAvert
Brief summary:
Conditions
Healthy Adult Participants
Age 65 and Older
Age 18 to 40
Immunology
Study ID
NCT07914673
Start date
Sep 25, 2026
Status verified date
Oct, 2026
Completion date
Sep 25, 2027
Anticipated
Primary completion date
Feb 1, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
40 participants
Anticipated
Intervention Model
Single group
Primary purpose
Basic Science
Arms
experimental: Vaccination
Interventions
Trivalent inactivated influenza vaccine
RabAvert
Primary outcome measure
Central contacts
Locations
Washington University
Recruiting
St Louis, Missouri, United States, 63110
Contacts
Principal Investigator:
Patrick Olson, MD
Sponsor
Washington University School of Medicine
Last update posted
Nov 3, 2026
Last verified
Oct, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-04. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2026-11-03. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.